Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Gilbert

Showing results (181-190 of 453) with videos related to

Pageof 46
Sort By:
BMC Cancer|March 22, 2023
Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trialAmanda L King, Alvina A Acquaye-Mallory, Elizabeth Vera, et al.
Neuro-Oncology|February 4, 2015
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trialKathleen M Schmainda, Zheng Zhang, Melissa Prah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastomaMichael E Scheurer, E Amirian, Yumei Cao, et al.
Cancers|July 2, 2021
Targeting CDK9 for the Treatment of GlioblastomaAlice Ranjan, Ying Pang, Madison Butler, et al.
Journal of Neuro-Oncology|July 16, 2016
Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying)Quinn T Ostrom, Haley Gittleman, Carol Kruchko, et al.
Cancers|June 25, 2020
Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant GliomaVictor Ruiz-Rodado, Tomohiro Seki, Tyrone Dowdy, et al.
Neuro-Oncology|January 31, 2009
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factorsTerri S Armstrong, Yumei Cao, Michael E Scheurer, et al.
Neuro-Oncology|July 10, 2010
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label studyW K Alfred Yung, James J Vredenburgh, Timothy F Cloughesy, et al.
Translational Oncology|December 23, 2019
Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/β-Catenin Signaling in IDH1-mutant GliomasYiqiang Zhou, Yang Liu, Junwen Zhang, et al.
Journal of Neuro-Oncology|August 30, 2014
Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institutionJacob J Mandel, Shlomit Yust-Katz, David Cachia, et al.
Pageof 46

Showing results (181-190 of 453) with videos related to

Sort By:
Pageof 46
BMC Cancer|March 22, 2023
Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trialAmanda L King, Alvina A Acquaye-Mallory, Elizabeth Vera, et al.
Neuro-Oncology|February 4, 2015
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trialKathleen M Schmainda, Zheng Zhang, Melissa Prah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastomaMichael E Scheurer, E Amirian, Yumei Cao, et al.
Cancers|July 2, 2021
Targeting CDK9 for the Treatment of GlioblastomaAlice Ranjan, Ying Pang, Madison Butler, et al.
Journal of Neuro-Oncology|July 16, 2016
Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying)Quinn T Ostrom, Haley Gittleman, Carol Kruchko, et al.
Cancers|June 25, 2020
Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant GliomaVictor Ruiz-Rodado, Tomohiro Seki, Tyrone Dowdy, et al.
Neuro-Oncology|January 31, 2009
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factorsTerri S Armstrong, Yumei Cao, Michael E Scheurer, et al.
Neuro-Oncology|July 10, 2010
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label studyW K Alfred Yung, James J Vredenburgh, Timothy F Cloughesy, et al.
Translational Oncology|December 23, 2019
Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/β-Catenin Signaling in IDH1-mutant GliomasYiqiang Zhou, Yang Liu, Junwen Zhang, et al.
Journal of Neuro-Oncology|August 30, 2014
Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institutionJacob J Mandel, Shlomit Yust-Katz, David Cachia, et al.
Pageof 46